Skip to main content
IDXXIDEXX Laboratories, Inc.Buy Wait5.7·$672.04

IDEXX Laboratories (IDXX) Q2 2026 earnings — TrendMatrix coverage

BEAT+8.5% vs estimateEPS $4.27 vs $3.93 estCurrent verdict Buy (Wait) 5.7/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q2 2026

Key numbers

Adjusted EPS
$4.27
Estimate
$3.93
Surprise
+8.5%
Revenue (period 2026-06-30)
$1.22B
Score today
5.7/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

IDEXX Laboratories (IDXX) beat the $3.93 estimate with adjusted EPS of $4.27 — a clear 8.5% upside surprise.

Current read · as of 2026-11-03

Where TrendMatrix's rating stands now

TrendMatrix currently rates IDXX Buy (Wait) at 5.7/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +8.5% surprise compares with a +5.8% four-quarter average. Next scheduled report: 2026-11-02.

What supports the rating

  • V7 flight-to-quality bonus: +0.5 (Q=8.4 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Concentration risk — Supplier: Ortho-Clinical Diagnostics
  • Analyst target reached - limited upside remaining
  • Expensive valuation

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$672.04
Entry target
$647.62
Stop
$602.29

The stock trades at 47.2× trailing but 40.1× forward earnings — consensus estimates already build in a substantial earnings recovery.

Risk check: RSI 80 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 1.7× its average — elevated turnover around the report window.

Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.

Healthcare context

IDXX at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Diagnostics & Research
Market cap
$52.98B
P/E (fwd)
40.1
P/E (ttm)
47.2
52-week range
$500.61–$769.98
Off 52-week high
12.7%
RSI (14)
80
Volume vs avg
1.73×
Score today
5.7/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › IDXX › Earnings › Q2 2026 earnings